期刊文献+

Binding Mode of Insulin Receptor and Agonist Peptide

Binding Mode of Insulin Receptor and Agonist Peptide
下载PDF
导出
摘要 Insulin is a protein hormone secreted by pancreatic β cells. One of its main functions is to keep the balance of glucose inside the body by regulating the absorption and metabolism of glucose in the periphery tissue, as well as the production and storage of hepatic glycogen. The insulin receptor is a transmembrane glycoprotein in which two a subunits with a molecular weight of 135 kD and two,8 subunits with a molecular weight of 95 kD are joined by a disulfide bond to form a β-α-α-β structure. The extracellular a subunit, especially, its three domains near the N-terminal are partially responsible for signal transduction or ligand-binding, as indicated by the experiments. The extracellular α subunits are involved in binding the ligands. The experimental results indicate that the three domains of the N-terminal of the a subunits are the main determinative parts of the insulin receptor to bind the insulin or mimetic peptide. We employed the extracellular domain( PDBID: 1IGR) of the insulin-like growth factor-1 receptor (IGF-1R) as the template to simulate and optimize the spatial structures of the three domains in the extracellular domain of the insulin receptor, which includes 468 residues. The work was accomplished by making use of the homology program in the Insight Ⅱ package on an Origin3800 server. The docking calculations of the insulin receptor obtained by homology with hexapeptides were carried out by means of the program Affinity. The analysis indicated that there were hydrogen bonding, and electrostatic and hydrophobic effects in the docking complex of the insulin receptor with hexapeptides. Moreover, we described the spatial orientation of a mimetic peptide with agonist activity in the docking complex. We obtained a rough model of binding of DLAPSQ or STIVYS with the insulin receptor, which provides the powerful theoretical support for designing the minimal insulin mimetic peptide with agonist activity, making it possible to develop oral small molecular hypoglycemic drugs. Insulin is a protein hormone secreted by pancreatic β cells. One of its main functions is to keep the balance of glucose inside the body by regulating the absorption and metabolism of glucose in the periphery tissue, as well as the production and storage of hepatic glycogen. The insulin receptor is a transmembrane glycoprotein in which two a subunits with a molecular weight of 135 kD and two,8 subunits with a molecular weight of 95 kD are joined by a disulfide bond to form a β-α-α-β structure. The extracellular a subunit, especially, its three domains near the N-terminal are partially responsible for signal transduction or ligand-binding, as indicated by the experiments. The extracellular α subunits are involved in binding the ligands. The experimental results indicate that the three domains of the N-terminal of the a subunits are the main determinative parts of the insulin receptor to bind the insulin or mimetic peptide. We employed the extracellular domain( PDBID: 1IGR) of the insulin-like growth factor-1 receptor (IGF-1R) as the template to simulate and optimize the spatial structures of the three domains in the extracellular domain of the insulin receptor, which includes 468 residues. The work was accomplished by making use of the homology program in the Insight Ⅱ package on an Origin3800 server. The docking calculations of the insulin receptor obtained by homology with hexapeptides were carried out by means of the program Affinity. The analysis indicated that there were hydrogen bonding, and electrostatic and hydrophobic effects in the docking complex of the insulin receptor with hexapeptides. Moreover, we described the spatial orientation of a mimetic peptide with agonist activity in the docking complex. We obtained a rough model of binding of DLAPSQ or STIVYS with the insulin receptor, which provides the powerful theoretical support for designing the minimal insulin mimetic peptide with agonist activity, making it possible to develop oral small molecular hypoglycemic drugs.
出处 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2006年第2期242-244,共3页 高等学校化学研究(英文版)
关键词 INSULIN Insulin receptor Mimetic peptide HOMOLOGY DOCKING Insulin Insulin receptor Mimetic peptide Homology Docking
  • 相关文献

参考文献15

  • 1Geysen H. M., Rodds S. J., Mason T. J., Mol. lmmunol,1986, 23,709
  • 2Rao G. S. , Bhatnagar S. , Ahuja V. , J. Biomol Street. Dyn. ,2002, 20(1), 31
  • 3Yue Jun-jie, Dai Qiu-yun, Wang Guo-li, et al. , Letters in Biotechnology, 2002, 13(4), 281
  • 4Renuka C. Pillutla, Ku-chuan Hsiao, et al. , J. Biol. Chem. ,2002, 277, 22590
  • 5Qing X, H. , Shoelson S, E, , Kochoya M. , et al. , Nature,1991, 354, 238.
  • 6Luo Z-T. R. , Beniac R. D. , Femandes A. , et al. , Science,1999, 285, 1077
  • 7Lauge Schaffer, Renee E, B. , Jane C. S. , et al. , Proc, Natl.Acad. Sci., 2003, 100, 4435
  • 8Piao Jin-hua, Li Hong-mei, Wang Li-ping, et al. , Journal of Jilin University( Science Edition), 2003, 41 (3) , 384
  • 9Homology User Guide, MSI, San Diego, 1999
  • 10Garrett P. J. , MeKern N. M. , Lou Mei-zhen, et al. , Nature,1998, 394,395

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部